Stress-Induced EGFR Trafficking: Mechanisms, Functions, and Therapeutic Implications

Trends in Cell Biology

Volumn 26, Issue 5, 2016, Pages 352-366

  Tan, Xiaojun ^a   Lambert, Paul F ^a,b   Rapraeger, Alan C ^a   Anderson, Richard A ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Autophagy; Cancer therapy; Cellular stress; EGFR; Ligand independent trafficking

Indexed keywords

CAVEOLIN; EPIDERMAL GROWTH FACTOR RECEPTOR; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN TYROSINE KINASE;

AUTOPHAGY; CANCER CELL; CANCER THERAPY; CELL STRESS; CELL SURVIVAL; ENDOSOME; INTERNALIZATION; INTRACELLULAR SIGNALING; INTRACELLULAR TRANSPORT; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; ANIMAL; HUMAN; METABOLISM; NEOPLASM; PHYSIOLOGICAL STRESS; PROTEIN TRANSPORT;

ANIMALS; AUTOPHAGY; ENDOSOMES; HUMANS; NEOPLASMS; PROTEIN TRANSPORT; RECEPTOR, EPIDERMAL GROWTH FACTOR; STRESS, PHYSIOLOGICAL;

EID: 84955605521     PISSN: 09628924     EISSN: 18793088     Source Type: Journal    
DOI: 10.1016/j.tcb.2015.12.006     Document Type: Review

References (121)

1. Lemmon M.A., Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141:1117-1134.
2. Mendelsohn J., Baselga J. Epidermal growth factor receptor targeting in cancer. Semin. Oncol. 2006, 33:369-385.
3. Jones S., Rappoport J.Z. Interdependent epidermal growth factor receptor signalling and trafficking. Int. J. Biochem. Cell Biol. 2014, 51:23-28.
4. Sorkin A., von Zastrow M. Endocytosis and signalling: intertwining molecular networks. Nat. Rev. Mol. Cell Biol. 2009, 10:609-622.
5. Wiley H.S. Trafficking of the ErbB receptors and its influence on signaling. Exp. Cell Res. 2003, 284:78-88.
6. Eden E.R., et al. The role of EGF receptor ubiquitination in regulating its intracellular traffic. Traffic 2012, 13:329-337.
7. Kolch W., Pitt A. Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat. Rev. Cancer 2010, 10:618-629.
8. Roepstorff K., et al. Differential effects of EGFR ligands on endocytic sorting of the receptor. Traffic 2009, 10:1115-1127.
9. Raiborg C., Stenmark H. The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins. Nature 2009, 458:445-452.
10. Henne W.M., et al. The ESCRT pathway. Dev. Cell 2011, 21:77-91.
11. Yue X., et al. Mitochondrially localized EGFR is subjected to autophagic regulation and implicated in cell survival. Autophagy 2008, 4:641-649.
12. Demory M.L., et al. Epidermal growth factor receptor translocation to the mitochondria: regulation and effect. J. Biol. Chem. 2009, 284:36592-36604.
13. Yao Y., et al. Mitochondrially localized EGFR is independent of its endocytosis and associates with cell viability. Acta Biochim. Biophys. Sin. 2010, 42:763-770.
14. Li C., et al. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 2009, 28:3801-3813.
15. Wang S.C., Hung M.C. Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clin. Cancer Res. 2009, 15:6484-6489.
16. Lo H.W. Nuclear mode of the EGFR signaling network: biology, prognostic value, and therapeutic implications. Discov. Med. 2010, 10:44-51.
17. Paez J.G., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
18. Health Quality O. Epidermal growth factor receptor mutation (EGFR) testing for prediction of response to EGFR-targeting tyrosine kinase inhibitor (TKI) drugs in patients with advanced non-small-cell lung cancer: an evidence-based analysis. Ont. Health Technol. Assess. Ser. 2010, 10:1-48.
19. Luca A.D., Normanno N. Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer. Curr. Drug Targets 2010, 11:851-864.
20. Chung C. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics. J. Oncol. Pharm. Pract. 2015.
21. Ellis P.M., et al. Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review. Curr. Oncol. 2015, 22:e183-e215.
22. Tan X., et al. A kinase-independent role for EGF receptor in autophagy initiation. Cell 2015, 160:145-160.
23. Lazova R., et al. Punctate LC3B expression is a common feature of solid tumors and associated with proliferation, metastasis, and poor outcome. Clin. Cancer Res. 2012, 18:370-379.
24. Franovic A., et al. Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:13092-13097.
25. Lum J.J., et al. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 2005, 120:237-248.
26. Lamb C.A., et al. The autophagosome: origins unknown, biogenesis complex. Nat. Rev. Mol. Cell Biol. 2013, 14:759-774.
27. Shibutani S.T., Yoshimori T. A current perspective of autophagosome biogenesis. Cell Res. 2014, 24:58-68.
28. Tomas A., et al. EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol. 2014, 24:26-34.
29. Wei Y., et al. EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. Cell 2013, 154:1269-1284.
30. Tan X., et al. LAPTM4B is a PtdIns(4,5)P2 effector that regulates EGFR signaling, lysosomal sorting, and degradation. EMBO J. 2015, 34:475-490.
31. Shao G., et al. Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene 2003, 22:5060-5069.
32. Kasper G., et al. The human LAPTM4b transcript is upregulated in various types of solid tumours and seems to play a dual functional role during tumour progression. Cancer Lett. 2005, 224:93-103.
33. Tomas A., et al. WASH and Tsg101/ALIX-dependent diversion of stress-internalized EGFR from the canonical endocytic pathway. Nat. Commun. 2015, 6:7324.
34. Itakura E., et al. Beclin 1 forms two distinct phosphatidylinositol 3-kinase complexes with mammalian Atg14 and UVRAG. Mol. Biol. Cell 2008, 19:5360-5372.
35. Sun Q., et al. Identification of Barkor as a mammalian autophagy-specific factor for Beclin 1 and class III phosphatidylinositol 3-kinase. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:19211-19216.
36. Matsunaga K., et al. Two Beclin 1-binding proteins, Atg14L and Rubicon, reciprocally regulate autophagy at different stages. Nat. Cell Biol. 2009, 11:385-396.
37. Zhong Y., et al. Distinct regulation of autophagic activity by Atg14L and Rubicon associated with Beclin 1-phosphatidylinositol-3-kinase complex. Nat. Cell Biol. 2009, 11:468-476.
38. Sun Q., et al. The RUN domain of rubicon is important for hVps34 binding, lipid kinase inhibition, and autophagy suppression. J. Biol. Chem. 2011, 286:185-191.
39. Bodemann B.O., et al. RalB and the exocyst mediate the cellular starvation response by direct activation of autophagosome assembly. Cell 2011, 144:253-267.
40. Kulich I., et al. Arabidopsis exocyst subcomplex containing subunit EXO70B1 is involved in autophagy-related transport to the vacuole. Traffic 2013, 14:1155-1165.
41. Fung C., et al. EGFR tyrosine kinase inhibition induces autophagy in cancer cells. Cancer Biol. Ther. 2012, 13:1417-1424.
42. Han W., et al. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS ONE 2011, 6:e18691.
43. Li Y.Y., et al. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer. Lung Cancer 2013, 81:354-361.
44. Choi H.S., et al. Autophagy inhibition with monensin enhances cell cycle arrest and apoptosis induced by mTOR or epidermal growth factor receptor inhibitors in lung cancer cells. Tuberc. Respir. Dis. (Seoul) 2013, 75:9-17.
45. Eimer S., et al. Autophagy inhibition cooperates with erlotinib to induce glioblastoma cell death. Cancer Biol. Ther. 2011, 11:1017-1027.
46. Sobhakumari A., et al. NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells. Toxicol. Appl. Pharmacol. 2013, 272:736-745.
47. Zou Y., et al. The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib. J. Thorac. Oncol. 2013, 8:693-702.
48. Dragowska W.H., et al. Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer. PLoS ONE 2013, 8:e76503.
49. Sakuma Y., et al. Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells. Lab. Invest. 2013, 93:1137-1146.
50. Orcutt K.P., et al. Erlotinib-mediated inhibition of EGFR signaling induces metabolic oxidative stress through NOX4. Cancer Res. 2011, 71:3932-3940.
51. Filomeni G., et al. Oxidative stress and autophagy: the clash between damage and metabolic needs. Cell Death Differ. 2015, 22:377-388.
52. Zwang Y., Yarden Y. p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy. EMBO J. 2006, 25:4195-4206.
53. Oksvold M.P., et al. UV induces tyrosine kinase-independent internalisation and endosome arrest of the EGF receptor. J. Cell Sci. 2002, 115:793-803.
54. Oksvold M.P., et al. UV-radiation-induced internalization of the epidermal growth factor receptor requires distinct serine and tyrosine residues in the cytoplasmic carboxy-terminal domain. Radiat. Res. 2004, 161:685-691.
55. Vergarajauregui S., et al. Activation of p38 mitogen-activated protein kinase promotes epidermal growth factor receptor internalization. Traffic 2006, 7:686-698.
56. Tong J., et al. Proteomic analysis of the epidermal growth factor receptor (EGFR) interactome and post-translational modifications associated with receptor endocytosis in response to EGF and stress. Mol. Cell. Proteomics 2014, 13:1644-1658.
57. Tong J., et al. Epidermal growth factor receptor phosphorylation sites Ser991 and Tyr998 are implicated in the regulation of receptor endocytosis and phosphorylations at Ser1039 and Thr1041. Mol. Cell. Proteomics 2009, 8:2131-2144.
58. He Y-Y., et al. Epidermal growth factor receptor down-regulation induced by UVA in human keratinocytes does not require the receptor kinase activity. J. Biol. Chem. 2003, 278:42457-42465.
59. Wang J., Wu G.S. Role of autophagy in cisplatin resistance in ovarian cancer cells. J. Biol. Chem. 2014, 289:17163-17173.
60. Harhaji-Trajkovic L., et al. AMPK-mediated autophagy inhibits apoptosis in cisplatin-treated tumour cells. J. Cell. Mol. Med. 2009, 13:3644-3654.
61. Liu D., et al. Inhibition of autophagy by 3-MA potentiates cisplatin-induced apoptosis in esophageal squamous cell carcinoma cells. Med. Oncol. 2011, 28:105-111.
62. Garcia-Cano J., et al. Exploiting the potential of autophagy in cisplatin therapy: a new strategy to overcome resistance. Oncotarget 2015, 6:15551-15565.
63. Bao L., et al. Induction of autophagy contributes to cisplatin resistance in human ovarian cancer cells. Mol. Med. Rep. 2015, 11:91-98.
64. Misovic M., et al. Short-term exposure to UV-A, UV-B, and UV-C irradiation induces alteration in cytoskeleton and autophagy in human keratinocytes. Ultrastruct. Pathol. 2013, 37:241-248.
65. Chen L-H., et al. Targeting protective autophagy exacerbates UV-triggered apoptotic cell death. Int. J. Mol. Sci. 2012, 13:1209-1224.
66. Zhao Y., et al. Autophagy is induced by UVA and promotes removal of oxidized phospholipids and protein aggregates in epidermal keratinocytes. J. Invest. Dermatol. 2013, 133:1629-1637.
67. Shen J., et al. EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature 2013, 497:383-387.
68. Mishra O.P., Delivoria-Papadopoulos M. Effect of hypoxia on activation of epidermal growth factor receptor (EGFR) kinase and Src kinase in the cerebral cortex of newborn piglets. FASEB J. 2006, 20:LB115.
69. Fang Y., et al. Signaling pathways and mechanisms of hypoxia-induced autophagy in the animal cells. Cell Biol. Int. 2015, 39:891-898.
70. Ravid T., et al. Epidermal growth factor receptor activation under oxidative stress fails to promote c-Cbl mediated down-regulation. J. Biol. Chem. 2002, 277:31214-31219.
71. Filosto S., et al. EGF receptor exposed to oxidative stress acquires abnormal phosphorylation and aberrant activated conformation that impairs canonical dimerization. PLoS ONE 2011, 6:e23240.
72. Lee S-R., et al. Reversible inactivation of protein-tyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor. J. Biol. Chem. 1998, 273:15366-15372.
73. Denu J.M., Tanner K.G. Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: evidence for a sulfenic acid intermediate and implications for redox regulation. Biochemistry 1998, 37:5633-5642.
74. Avraham R., Yarden Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat. Rev. Mol. Cell Biol. 2011, 12:104-117.
75. Khan E.M., et al. Epidermal growth factor receptor exposed to oxidative stress undergoes src- and caveolin-1-dependent perinuclear trafficking. J. Biol. Chem. 2006, 281:14486-14493.
76. Norambuena A.s., et al. Phosphatidic acid induces ligand-independent epidermal growth factor receptor endocytic traffic through PDE4 activation. Mol. Biol. Cell 2010, 21:2916-2929.
77. Salazar G., Gonzalez A. Novel mechanism for regulation of epidermal growth factor receptor endocytosis revealed by Protein Kinase A inhibition. Mol. Biol. Cell 2002, 13:1677-1693.
78. Stephan J.S., et al. The Tor and PKA signaling pathways independently target the Atg1/Atg13 protein kinase complex to control autophagy. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:17049-17054.
79. Torres-Quiroz F., et al. Feedback regulation between autophagy and PKA. Autophagy 2015, 11:1181-1183.
80. Filteau M., et al. Systematic identification of signal integration by protein kinase A. Proc. Natl. Acad. Sci. U.S.A. 2015, 112:4501-4506.
81. Dittmann K., et al. Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK. Mol. Cancer 2008, 7:69.
82. Liao H-J., Carpenter G. Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor. Cancer Res. 2009, 69:6179-6183.
83. Brand T.M., et al. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol. Ther. 2011, 11:777-792.
84. Li X., et al. Roles of autophagy in cetuximab-mediated cancer therapy against EGFR. Autophagy 2010, 6:1066-1077.
85. Li X., Fan Z. The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1a and Bcl-2 and activating the Beclin 1/hVps34 complex. Cancer Res. 2010, 70:5942-5952.
86. Schmidt-Ullrich R.K., et al. Altered expression of epidermal growth factor receptor and estrogen receptor in MCF-7 cells after single and repeated radiation exposures. Int. J. Radiat. Oncol. Biol. Phys. 1994, 29:813-819.
87. Wanner G., et al. Activation of protein kinase Ce[open] stimulates DNA-repair via epidermal growth factor receptor nuclear accumulation. Radiother. Oncol. 2008, 86:383-390.
88. Bao J., et al. Threonine phosphorylation diverts internalized epidermal growth factor receptors from a degradative pathway to the recycling endosome. J. Biol. Chem. 2000, 275:26178-26186.
89. Xu Y., et al. Ultraviolet irradiation-induces epidermal growth factor receptor (EGFR) nuclear translocation in human keratinocytes. J. Cell. Biochem. 2009, 107:873-880.
90. Nijkamp M.M., et al. Interaction of EGFR with the tumour microenvironment: implications for radiation treatment. Radiother. Oncol. 2013, 108:17-23.
91. Chaachouay H., et al. Autophagy contributes to resistance of tumor cells to ionizing radiation. Radiother. Oncol. 2011, 99:287-292.
92. Koukourakis M.I., et al. Intensified autophagy compromises the efficacy of radiotherapy against prostate cancer. Biochem. Biophys. Res. Commun. 2015, 461:268-274.
93. Zhu H., et al. EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity. Cancer Lett. 2010, 294:101-110.
94. Che T.F., et al. Mitochondrial translocation of EGFR regulates mitochondria dynamics and promotes metastasis in NSCLC. Oncotarget 2015, 6:37349-37366.
95. Bollu L.R., et al. Involvement of de novo synthesized palmitate and mitochondrial EGFR in EGF induced mitochondrial fusion of cancer cells. Cell Cycle 2014, 13:2415-2430.
96. Cao X., et al. EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocalization: apotential mechanism of EGFR-driven antagonism of apoptosis. Mol. Cancer 2011, 10:26.
97. Dreier A., et al. Cetuximab induces mitochondrial translocalization of EGFRvIII, but not EGFR: involvement of mitochondria in tumor drug resistance?. Tumor Biol. 2012, 33:85-94.
98. Jutten B., et al. EGFR overexpressing cells and tumors are dependent on autophagy for growth and survival. Radiother. Oncol. 2013, 108:479-483.
99. Jutten B., Rouschop K.M. EGFR signaling and autophagy dependence for growth, survival, and therapy resistance. Cell Cycle 2014, 13:42-51.
100. Shaughnessy R., et al. Epidermal growth factor receptor endocytic traffic perturbation by phosphatidate phosphohydrolase inhibition: new strategy against cancer. FEBS J. 2014, 281:2172-2189.
101. Karnthaler-Benbakka C., et al. Tumor-targeting of EGFR inhibitors by hypoxia-mediated activation. Angew. Chem. Int. Ed. 2014, 53:12930-12935.
102. Miettinen P.J., et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 1995, 376:337-341.
103. Threadgill D.W., et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 1995, 269:230-234.
104. Sibilia M., Wagner E.F. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 1995, 269:234-238.
105. Luetteke N.C., et al. The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase. Genes Dev. 1994, 8:399-413.
106. Kancha R.K., et al. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Clin. Cancer Res. 2009, 15:460-467.
107. Weihua Z., et al. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 2008, 13:385-393.
108. Coker K.J., et al. A kinase-negative epidermal growth factor receptor that retains the capacity to stimulate DNA synthesis. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:6967-6971.
109. Ewald J.A., et al. Ligand- and kinase activity-independent cell survival mediated by the epidermal growth factor receptor expressed in 32D cells. Exp. Cell Res. 2003, 282:121-131.
110. Eldredge E.R., et al. Activation of c-fos gene expression by a kinase-deficient epidermal growth factor receptor. Mol. Cell. Biol. 1994, 14:7527-7534.
111. Hanabata Y., et al. Coexpression of SGLT1 and EGFR is associated with tumor differentiation in oral squamous cell carcinoma. Odontology 2012, 100:156-163.
112. Henriksen L., et al. Internalization mechanisms of the epidermal growth factor receptor after activation with different ligands. PLoS ONE 2013, 8:e58148.
113. Lin S.Y., et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell Biol. 2001, 3:802-808.
114. Choi E.J., et al. Targeting epidermal growth factor receptor-associated signaling pathways in non-small cell lung cancer cells: implication in radiation response. Mol. Cancer Res. 2010, 8:1027-1036.
115. Sartor C.I. Epidermal growth factor family receptors and inhibitors: radiation response modulators. Semin. Radiat. Oncol. 2003, 13:22-30.
116. Hamasaki M., et al. Autophagosomes form at ER-mitochondria contact sites. Nature 2013, 495:389-393.
117. Fader C.M., Colombo M.I. Autophagy and multivesicular bodies: two closely related partners. Cell Death Differ. 2008, 16:70-78.
118. Eden E.R., et al. Membrane contacts between endosomes and ER provide sites for PTP1B-epidermal growth factor receptor interaction. Nat. Cell Biol. 2010, 12:267-272.
119. Friedman J.R., et al. Endoplasmic reticulum-endosome contact increases as endosomes traffic and mature. Mol. Biol. Cell 2013, 24:1030-1040.
120. Raiborg C., et al. Repeated ER-endosome contacts promote endosome translocation and neurite outgrowth. Nature 2015, 520:234-238.
121. Raiborg C., et al. ER-endosome contact sites: molecular compositions and functions. EMBO J. 2015, 34:1848-1858.